• linkedin
  • Increase Font
  • Sharebar

    Failed lampalizumab studies offer numerous lessons about GA

    Although the phase III Chroma and Spectri studies for lampalizumab (Genentech), an investigational compound for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD), failed to meet their primary endpoints, numerous lessons can be learned from the study data, according to two experts.

    Jeffrey S. Heier, MD, and Frank G. Holz, MD, presented comprehensive data on lampalizumab, including genetics and long-term visual function outcomes that will help advance the understanding of geographic atrophy. Both presented their data at the 41st Annual Macula Society Meeting, held in February 2018,

    Dr. Heier is in private practice at Ophthalmic Consultants of Boston. Dr. Holz is chairman and professor of ophthalmology, University of Bonn, Germany.

    Lampalizumab is a selective inhibitor of complement factor D. There has been genetic evidence the implicates the complement cascade dysregulation in geographic atrophy/AMD, Dr. Heier said, noting complement factor D is a rate-limiting enzyme of the alternate complement pathway with the lowest plasma concentrations of complement proteins. In a phase II study, geographic atrophy area progression was reduced by 20% from baseline to 18 months in the lampalizumab group compared to the sham group.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';